The Augmentation Effect of N-Acetyl Cysteine Antioxidant on Superoxide Dismutase Levels in Schizophrenic Patients Treated with Risperidone
DOI:
https://doi.org/10.3889/oamjms.2021.6354Keywords:
Schizophrenia, Superoxide dismutase, N-acetyl cysteineAbstract
Background: Schizophrenia affects approximately 1% of the population and in Indonesia the prevalence is about 400.000 people or as many as 1.7 per 10000 individuals of the population. Schizophrenia is characterized by positive symptoms, negative symptoms and also cognitive, aggressive, and affective symptoms, where negative symptoms reflect loss of function.One important factor that plays a role in the pathophysiology of schizophrenia is the excessive production of free radical substances and the failure of the anti-oxidant defense process.
The aim of this study is to see how levels of superoxide dismutase change after N-acetylcystein augmentation in schizophrenic patients treated with risperidone. This study is a pre-post experimental test design, where schizophrenic patients meet inclusion and exclusion criteria. At baseline, and after 8 weeks of N-acetyl cysteine administration, patients were assessed at each of the time points using PANSS, and SOD was measured in blood at both time points.
The average negative PANSS score in the Risperidone + NAC baseline group was 29.93 (±1.83); in the Risperidone group was 29.83 (±1.19) (p = 0.87). The average negative PANSS score at the end of week 8 was statistically significantly different (p = 0.001) in the Risperidone + NAC group (17.40 ±1.84) and in the Riseridone group (21.00±0.74). The average baseline SOD levels in the Risperidone + NAC group were 63.57 (±22.44), and in the Risperidone group was 85.79 (±101.05). SOD levels at week 8 in the Risperidone + NAC group were 71.72 (±31.20) and in the Risperidone group 128.27 (±117.67). ∆ SOD in the Risperidone + NAC group was 8.15 (19.54) and ∆ SOD in the Risperidone group was 42.48± (54.30). p value of 0.028Research data shows that NAC augmentation can improve the negative symptoms of schizophrenia through reducing SOD levels in the blood.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Ministry of Health of Republic Indonesia: Riset Kesehatan Dasarl; 2013. [Last accessed on 2021 May 12]. Available from: https://www.depkes.go.id.
Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(1):156-9. https://doi.org/10.1016/0003-2697(87)90021-2 PMid:2440339 DOI: https://doi.org/10.1016/0003-2697(87)90021-2
Remington G, Foussias G, Fervahana G, Agid O, Takeuchi H, Lee J, et al. Treating negative symptoms in schizophrenia: An update. Curr Treat Options Psychiatry 2016;3:133-50. https://doi.org/10.1007/s40501-016-0075-8 PMid:27376016 DOI: https://doi.org/10.1007/s40501-016-0075-8
Gunes M, Altindag A, Bulut M, Demir S, Ibiloglu A, Kaya M, et al. Oxidative metabolism may be associated with negative symptoms in schizophrenia. Psychiatry Clin Psycopharmacol. 2017;27(1):54-61. https://doi.org/10.1080/24750573.2017.1293243 DOI: https://doi.org/10.1080/24750573.2017.1293243
Uma D, Chinnaswamy P. Oxidative injury and enzymic antioxidant misbalance in schizophrenics with positive, negative and cognitive symptoms. Afr J Biochem Res. 2008;2(4):92-7.
Djordjevic V, Lazarevis D, Cosic V, Knezevic M, Djordjevic V. Age-related changes of superoxide dismutase activity in patients with schizophrenia. Vojnosanit Pregl. 2017;74(1):31-7. https://doi.org/10.2298/vsp141202142d DOI: https://doi.org/10.2298/VSP141202142D
Farokhnia M, Azarkolah A, Adinehfar F, Khodaiae-arkadani M, Hosseini S, Yekehtaz H, et al. N-acetylcisteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. Clin Neuropharmacol. 2013;36(6):185-92. https://doi.org/10.1097/wnf.0000000000000001 PMid:24201233 DOI: https://doi.org/10.1097/WNF.0000000000000001
Berk M, Malhi G, Gray L, Dean O. The promise of n-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci. 2013;34(3):167-77. https://doi.org/10.1016/j.tips.2013.01.001 PMid:23369637 DOI: https://doi.org/10.1016/j.tips.2013.01.001
Bioassay Technology Laboratory, Human Superoxidase Dismutase ELISA. [Last accessed on 2021 May 12]. Available from: https://www.bt-laboratory.com.
Pazvantoglu O, Selek S, Okay T, Sengul C, Koray K, Dilbaz N, et al. Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile. Psychiatry Clin Neurosci. 2009;63(5):693-700. https://doi.org/10.1111/j.1440-1819.2009.02015.x PMid:19788631 DOI: https://doi.org/10.1111/j.1440-1819.2009.02015.x
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Vita Camellia, Khairunnisa Khairunnisa, Muhammad Ichwan, Muhammad Surya Husada, Elmeida Effendy, Rusdiana Rusdiana, Deasy Hendriaty (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0